Immune cells of the brain renew hopes for curing Alzheimer's disease

November 30, 2012

A new experimental study carried out in mice shows that microglia, immune cells of the brain, might play a key role in protecting the brain from Alzheimer's disease (AD). It is long believed that toxic sticky protein deposits in the brain called amyloid beta (Aβ) are responsible for loss of memory in AD patients. Earlier studies have shown that microglia can remove Aβ protein from the brain and therefore be vital for successful therapy. Interestingly, the doctoral thesis of Mr Lakshman Kumar Puli, MPharm (Pharmacology), indicates that microglia may play a significant role irrespective of their capacity to remove brain Aβ deposits.

These Aβ deposits initiate inflammation inside the brain. It is not clearly known if this inflammation is good or bad. Harmful fires up microglia, which may interfere with the normal functioning of or even kill them. However, according to this new study, stopping harmful activation of microglia is feasible even without the removal of Aβ protein from the brain.

Mr Puli's doctoral thesis titled "Experimental Immunomodulation in Alzheimer's disease" utilizes two different approaches to suppress harmful activation of microglia. Firstly, genetically modified mice with Alzheimer's disease when treated with polyclonal human intravenous immunoglobulins (IVIG) suppressed harmful activation of microglia and, surprisingly, also promoted the survival of newly born neurons in the hippocampus of the brain, which is regarded as the seat of memory. This is the first experimental study to suggest that IVIG can promote the survival of newly born neurons in the .

IVIG is currently in the clinical trials in AD patients. In humans, IVIG has been reported to have stopped the progression of AD in a small number of patients for a remarkable period of three years. The mechanism remains unknown, but Mr Puli's experimental work suggests that IVIG might promote the clinical benefits in AD patients by suppressing harmful activation of microglia and enhancing the survival of newly born in the brain.

"These studies have revealed some very important new mechanisms by which treatment with naturally occurring human antibodies can potentially benefit persons with Alzheimer's disease and other age related disorders," says Dr Norman Relkin (Weill Cornell Memory Disorders Program, New York, USA), who is leading the Gammaglobulin Alzheimer Partnership (GAP) Phase 3 Study of IVIG for Alzheimer's disease.

In the second approach, Mr Puli and his fellow researchers used a novel genetically modified mouse that lacks the key gene responsible for brain inflammation. Removal of this Nfkb1 gene greatly suppressed activation of microglia irrespective of its capacity to remove Aβ protein from the brain. However, in this study it was not clear if such a suppression is good or bad. Both these experiments clearly indicate that microglia can be influenced in a way which is beneficial for AD patients.

Explore further: The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage

Related Stories

The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage

March 19, 2012
Microglia are the first line defence of the brain and are constantly looking for infections to fight off. Overactive microglia can cause uncontrolled inflammation within the brain, which can in turn lead to neuronal damage. ...

Gardening in the brain: Specialist cells prune connections between neurons

July 21, 2011
Gardeners know that some trees require regular pruning: some of their branches have to be cut so that others can grow stronger. The same is true of the developing brain: cells called microglia prune the connections between ...

Study examines role of microglial cells as both defenders and fighters in the nervous system

October 16, 2012
(Medical Xpress)—In many pathologies of the nervous system, there is a common event - cells called microglia are activated from surveillant watchmen into fighters.  Microglia are the immune cells of the nervous system, ...

Intravenous vaccination promotes brain plasticity and prevents memory loss in Alzheimer's disease

April 23, 2012
Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disease affecting over five million people worldwide, and is the leading cause of dementia in the elderly. Currently, intravenous human immunoglobulin ...

Recommended for you

Could olfactory loss point to Alzheimer's disease?

August 16, 2017
By the time you start losing your memory, it's almost too late. That's because the damage to your brain associated with Alzheimer's disease (AD) may already have been going on for as long as twenty years. Which is why there ...

New Machine Learning program shows promise for early Alzheimer's diagnosis

August 15, 2017
A new machine learning program developed by researchers at Case Western Reserve University appears to outperform other methods for diagnosing Alzheimer's disease before symptoms begin to interfere with every day living, initial ...

Brain scan study adds to evidence that lower brain serotonin levels are linked to dementia

August 14, 2017
In a study looking at brain scans of people with mild loss of thought and memory ability, Johns Hopkins researchers report evidence of lower levels of the serotonin transporter—a natural brain chemical that regulates mood, ...

Alzheimer's risk linked to energy shortage in brain's immune cells

August 14, 2017
People with specific mutations in the gene TREM2 are three times more likely to develop Alzheimer's disease than those who carry more common variants of the gene. But until now, scientists had no explanation for the link.

Scientists reveal role for lysosome transport in Alzheimer's disease progression

August 7, 2017
Researchers from Yale University School of Medicine have discovered that defects in the transport of lysosomes within neurons promote the buildup of protein aggregates in the brains of mice with Alzheimer's disease. The study, ...

Mild cognitive impairment and Alzheimer's diagnoses trigger lower self-ratings of quality of life

August 3, 2017
Researchers at Penn Medicine have discovered that a patient's awareness of a diagnosis of cognitive impairment may diminish their self-assessment of quality of life. In a study published this month in the Journal of Gerontology: ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.